Silver Book Fact

About 1/2 of the decrease in recent deaths in cardiovascular disease can be attributed to medical treatment.

Ford, Earl S., Umed A. Ajani, Janet B. Croft, Julia A. Critchley, Darwin R. Labarthe, Thomas E. Kottke, Wayne H. Giles, and Simon Capewell. Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980-2000. New England Journal of Medicine. June 2007; 356: 2388-98. http://content.nejm.org/cgi/content/abstract/356/23/2388

Reference

Title
Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980-2000
Publication
New England Journal of Medicine
Publication Date
June 2007
Authors
Ford, Earl S., Umed A. Ajani, Janet B. Croft, Julia A. Critchley, Darwin R. Labarthe, Thomas E. Kottke, Wayne H. Giles, and Simon Capewell
Pages
2388-98
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • TAVR improves quality of life in SAS patients
     
  • Following the current path, heart disease cases will increase by 41.1% between 2003 and 2023. If an alternative path is taken, there will be 34.6% (9.4 million) fewer heart disease…  
  • Without antihypertensive therapies, blood pressures (at age 40+) would have been between 10% and 13% higher in 1999-2000. Additionally, 86,000 excess premature deaths from cardiovascular disease would have occurred in…  
  • TAVR Success in sSAS Patients
    A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,…